BioSpace News Archive

SOLASCURE Ltd has announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase, a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.

Akero Therapeutics, Inc. released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3.

IDEAYA Biosciences, Inc. announced its participation in upcoming investor relations events.

Zura Bio Limited a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced that members of its senior management team will participate in three conferences in March.

Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study’s inclusion criteria.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted seven newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on March 1, 2024 as inducements material to each employee entering into employment with KalVista.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2023.

Revance Therapeutics, Inc. announced a proposed underwritten public offering of $100 million of its common stock.

Merck (NYSE: MRK) announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024, at 12:40 p.m. ET.